GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » Total Inventories

RYTM (Rhythm Pharmaceuticals) Total Inventories : $18.7 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Total Inventories?

Rhythm Pharmaceuticals's total inventories for the quarter that ended in Dec. 2024 was $18.7 Mil. Rhythm Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $16.3 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Rhythm Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-0.43.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Rhythm Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 was 393.19.

Inventory Turnover measures how fast the company turns over its inventory within a year. Rhythm Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.23.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Rhythm Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.39.


Rhythm Pharmaceuticals Total Inventories Historical Data

The historical data trend for Rhythm Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Total Inventories Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.11 2.92 8.62 18.74

Rhythm Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.62 8.51 11.99 13.90 18.74

Rhythm Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Rhythm Pharmaceuticals  (NAS:RYTM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Rhythm Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

Net-Net Working Capital Per Share (Q: Dec. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(320.565+0.75 * 18.512+0.5 * 18.741-227.724
-142.82-0)/62.391
=-0.43

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Rhythm Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=16.318/3.787*365 / 4
=393.19

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Rhythm Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2024 ) / Average Total Inventories (Q: Dec. 2024 )
=3.787 / 16.318
=0.23

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Rhythm Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=16.318 / 41.83
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Rhythm Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Executives
Yann Mazabraud officer: EVP, Head of International C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Christopher Paul German officer: Corporate Controller & CAO C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Pamela J. Cramer officer: Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Joseph Shulman officer: Chief Technical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith officer: CFO and Treasurer C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien officer: EVP, Head of North America C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
William T. Roberts officer: Chief Accounting Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning officer: Chief Medical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan officer: Chief Commercial Officer 82 BAY STATE ROAD, BELMONT MA 02478